EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

Tadao Akizawa iD, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura iD

Therapeutic Apheresis and Dialysis · 2026-12 · 30 (6) · 908-924

DOI: 10.1002/1744-9987.70182 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 06.07.2026. Verfasst von Tadao Akizawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Showa Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Anemia, Renal Insufficiency, Chronic, Prolyl-Hydroxylase Inhibitors. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan.

Methods

Patients who initiated daprodustat between September 2020 and July 2022 were registered. The observation period was 52 weeks from treatment start or until discontinuation to assess overall safety, with an additional 52‐week follow‐up for cancer‐related events.

Results

Of 1634 patients in the safety analysis set, adverse drug reactions (ADRs) occurred in 5.6% (4.8% not undergoing dialysis; 6.9% undergoing peritoneal dialysis; 6.6% undergoing hemodialysis) and serious ADRs in 2.2%. ADRs related to thromboembolism, hypertension, cardiovascular events, cancer, and retinal hemorrhage were reported in less than 1%, with no progression of autosomal dominant polycystic kidney disease. During follow‐up, no increase in cancer‐related events was observed.

Conclusions

No new safety concerns were identified for daprodustat in the real‐world setting in Japan. Trial Registration: GSK study: 214119

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaRenal Insufficiency, ChronicProlyl-Hydroxylase InhibitorsAgedFemaleHumansMaleMiddle AgedJapanProduct Surveillance, PostmarketingProspective StudiesRenal DialysisHypoxia-Inducible Factor-Proline DioxygenasesCyclohexanesPyrimidines

Stichwörter der Autor:innen

anemiachronic kidney diseasedaprodustatpostmarketing surveillance study

Substanzen

GSK1278863Prolyl-Hydroxylase InhibitorsHypoxia-Inducible Factor-Proline DioxygenasesCyclohexanesPyrimidines

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Showa Medical University, Tokyo, Japan.
  • Real-World Data Analytics, Biostatistics, Asia Development, GlaxoSmithKline K.K, Tokyo, Japan.
  • Safety Risk Evaluation, Clinical Safety & Pharmacovigilance, GlaxoSmithKline K.K, Tokyo, Japan.
  • Specialty Medical Affairs, Specialty Medical Affairs and Development, Japan Medical Affairs, GlaxoSmithKline K.K, Tokyo, Japan.
  • Safety Evaluation & Risk Management, Clinical Safety & Pharmacovigilance, GlaxoSmithKline K.K, Tokyo, Japan.
  • Real-World Evidence & Health Outcome Research, Japan Medical Affairs, GlaxoSmithKline K.K, Tokyo, Japan.

ORCID-Profile: Tadao Akizawa, Tomohiko Asamura

Förderung

  • GlaxoSmithKline

Zitieren

APA

Akizawa, T., Kanaya, K., Aizawa, K., Onoki, M., Ozeki, H., Suzuki, K., Hayashi, A., & Asamura, T. (2026). Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan. Therapeutic Apheresis and Dialysis, 30(6), 908-924. https://doi.org/10.1002/1744-9987.70182

Vancouver

Akizawa T, Kanaya K, Aizawa K, Onoki M, Ozeki H, Suzuki K, et al. Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan. Therapeutic Apheresis and Dialysis. 2026;30(6):908-924. doi:10.1002/1744-9987.70182

BibTeX
@article{Akizawa2026,
  author = {Akizawa, Tadao and Kanaya, Kyomi and Aizawa, Kiyomi and Onoki, Masanori and Ozeki, Hirofumi and Suzuki, Kazuko and Hayashi, Ai and Asamura, Tomohiko},
  title = {Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2026},
  volume = {30},
  number = {6},
  pages = {908--924},
  doi = {10.1002/1744-9987.70182}
}
Kostenlos starten →